Gyroscope Therapeutics has begun a phase 2 program to evaluate GT005, an investigational gene therapy for the treatment of geographic atrophy secondary to dry age-related macular degeneration, according to a press release.
EXPLORE is a multicenter, randomized trial that aims to evaluate the safety and efficacy of a single subretinal injection of GT005. Patients aged 55 years or older with a clinical diagnosis of geographic atrophy and a mutation of the CFI gene are being enrolled in the study. The trial will have three arms consisting of two different doses (Read more...)
Uncategorized